NasdaqGS - Nasdaq Real Time Price USD

Enanta Pharmaceuticals, Inc. (ENTA)

12.37 -0.11 (-0.88%)
At close: April 26 at 4:00 PM EDT
12.37 0.00 (0.00%)
After hours: April 26 at 4:20 PM EDT

Key Executives

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Dr. Jay R. Luly Ph.D. President, CEO & Director 1.25M 2.03M 1956
Mr. Paul J. Mellett Jr. Senior VP of Finance & Administration and CFO 666.84k 529.98k 1955
Dr. Yat Sun Or Ph.D. Senior VP of Research & Development and Chief Scientific Officer 729.31k 424.85k 1952
Mr. Nathaniel S. Gardiner J.D. Consultant 672.67k 49.14k 1954
Mr. Brendan Luu Senior Vice President of Business Development 622.86k -- 1975
Ms. Jennifer Viera Senior Director of Investor Relations & Corporate Communications -- -- --
Ms. Tara Lynn Kieffer Ph.D. Senior Vice President of New Product Strategy & Development 496.85k -- 1978
Dr. Scott T. Rottinghaus M.D. Senior VP & Chief Medical Officer 616.73k -- 1974

Enanta Pharmaceuticals, Inc.

500 Arsenal Street
Watertown, MA 02472
United States
617 607 0800 https://www.enanta.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
145

Description

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

Corporate Governance

Enanta Pharmaceuticals, Inc.’s ISS Governance QualityScore as of April 1, 2024 is 5. The pillar scores are Audit: 3; Board: 4; Shareholder Rights: 8; Compensation: 7.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

  • Mar 12, 2024
    8-K: Corporate Changes & Voting Matters
    See Full Filing
  • Feb 14, 2024
    CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission
    See Full Filing
  • Feb 08, 2024
    10-Q: Periodic Financial Reports
    See Full Filing
  • Feb 07, 2024
    8-K: Corporate Changes & Voting Matters
    See Full Filing
  • Feb 06, 2024
    CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission
    See Full Filing

Upcoming Events

May 06, 2024 - May 10, 2024
Enanta Pharmaceuticals, Inc. Earnings Call

Related Tickers

ITOS iTeos Therapeutics, Inc.
10.80
+1.89%
 
BCAB BioAtla, Inc.
2.5400
+12.89%
 
INVA Innoviva, Inc.
15.26
+1.80%
 
XNCR Xencor, Inc.
19.98
+3.90%
 
REPL Replimune Group, Inc.
6.42
+4.39%
 
PTGX Protagonist Therapeutics, Inc.
25.15
+1.99%
 
STRO Sutro Biopharma, Inc.
3.4200
0.00%
 
APGE Apogee Therapeutics, Inc.
47.13
+2.77%
 
IKNA Ikena Oncology, Inc.
1.3000
-0.76%
 
PRTC PureTech Health plc
28.50
+2.24%